keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 12,500 | |||
10 mg | 在庫あり | ¥ 17,000 | |||
25 mg | 在庫あり | ¥ 27,000 | |||
50 mg | 在庫あり | ¥ 40,000 | |||
100 mg | 在庫あり | ¥ 59,000 | |||
500 mg | 在庫あり | ¥ 146,500 |
説明 | Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3. |
ターゲット&IC50 | VEGFR2:6.5 nM, VEGFR1:30 nM, VEGFR3:15 nM |
In vitro | Tivozanib hydrochloride hydrate (0-100 nM; 24 hours) inhibited the proliferation of HUVEC cells[1]. |
In vivo | In the Calu-6 tumor-bearing athymic mice model, Tivozanib hydrochloride hydrate (0.04-1 mg/kg/day; orally, for 14-21 days) inhibits tumor growth, angiogenesis, and vascular permeability[1]. |
別名 | AV-951 hydrochloride hydrate, KRN951 hydrochloride hydrate |
分子量 | 509.34 |
分子式 | C22H22Cl2N4O6 |
CAS No. | 682745-41-1 |
keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (196.33 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tivozanib hydrochloride hydrate 682745-41-1 Angiogenesis Tyrosine Kinase/Adaptors VEGFR AV-951 hydrochloride hydrate KRN951 hydrochloride hydrate Inhibitor inhibitor inhibit